Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 25/100

Alto Neuroscience, Inc. Class Action: The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 – ANRO

Key Takeaway: Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit initiated by The Gross Law Firm, which seeks to represent investors who purchased shares during a specified class period. The allegations include misleading statements regarding the efficacy of the company's product, ALTO-100, in treating major depressive disorder and overstated business prospects. Shareholders are encouraged to register for participation in the lawsuit by the lead plaintiff deadline of September 19, 2025. The Gross Law Firm emphasizes its commitment to protecting investors' rights against corporate misconduct.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges that the company's product, ALTO-100, is less effective than claimed.
  • Claims of overstated clinical and commercial prospects for ALTO-100.
  • Investors were misled due to materially false statements made by the company.

Full Press Release Details

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO).
Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
DEADLINE: September 19, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=166908&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ANRO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 19, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for the Alto Neuroscience lawsuit?

The class period is from February 2, 2024, to October 22, 2024.

What allegations are made against Alto Neuroscience?

The lawsuit alleges misleading statements about the effectiveness of ALTO-100.

How can shareholders register for the class action?

Shareholders can register using the form linked in the notice before September 19, 2025.

Is there a fee to participate in the lawsuit?

There is no cost or obligation to participate in the case.

What support do registered shareholders receive?

Registered shareholders will receive updates via portfolio monitoring software.

Last updated: Sep 15, 2025